Organigram Holdings, Inc. (OTCQB: OGRMF), through its wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and Organigram is regulated by the Access to Cannabis for Medical Purposes Regulations.
Adult recreational use of cannabis in Canada is expected to be legalized in the summer of 2018. The company’s shares have jumped over 40% since April as the legalization date draws nearer.
Welcome to Traders News Source,
Stay tuned and keep an eye on your inbox for our next hot Small-Mid Cap stock report coming soon.
We have an outstanding track record for near-term gains in the Small Cap arena.
Do not forget to add us to your preferred/safe senders list within your email service provider. Expect one new Small Cap NASDAQ or NYSE listed company research report per week free of charge.
We only alert you to stocks we believe will offer up near-term trading profits.
Receive TEXT ALERTS the minute we initiate coverage
Text the word “Traders” to the number “25827” from your cell phone to receive small cap reports in real-time ahead of the crowd.
Update – We will be initiating coverage on an exciting NASDAQ small cap growth stock sporting a tiny float within the next few days!
May 24, 2018. Organigram Holdings announced that it has entered into a letter of intent with Hyasynth Biologicals, Inc. whereby Organigram proposes to make a strategic investment in Hyasynth. Additionally, the non-binding letter of intent contemplates Organigram entering into an off-take agreement with Hyasynth whereby Organigram can purchase a pre-defined quantity of a range of cannabinoids or cannabinoid related production from Hyasynth on terms set forth in such agreement. https://www.otcmarkets.com/stock/OGRMF/news/Organigram-Announces-Letter-of-Intent-for-Strategic-Investment-in-Hyasynth-Biologicals-Inc?id=193452
May 17, 2018 /CNW/ – Organigram announced that it has received a “Permit to Export Cannabis” from Health Canada that will allow the Company to begin its first international shipments. Organigram will now be able to ship dried cannabis products to Cannatrek Medical PTY Ltd, a licensed Australian medical cannabis enterprise with operations in Melbourne, Victoria through its broker Cannada Management Group Global Inc., a leading global cannabis and hemp brokerage firm for import/export, procurement and logistics of cannabis and hemp related products. https://www.otcmarkets.com/stock/OGRMF/news/Organigram-Receives-Permit-to-Export-Medical-Cannabis-to-Australia?id=192741
May 15, 2018. Organigram unveiled their Phase 1 branding strategy for the adult recreational market in Canada. Organigram’s unprecedented recreational portfolio will be officially launched once adult use recreational cannabis is legal in Canada and includes the launch of The Edison Cannabis Company, ANKR Organics and Trailer Park Buds. “Our recreational brand strategy incorporates the best of what we know about our current and potential customers, the industry and opportunities for growth, and the production of our premium products,” says Greg Engel, CEO, Organigram. “The addition of each of these brands is the result of more than 18 months of research, development and teamwork to better understand our products and consumers.” https://www.otcmarkets.com/stock/OGRMF/news/Organigram-Unveils-Comprehensive-Suite-of-Adult-Recreational-Cannabis-Brands?id=192395
A premium product, The Edison Cannabis Company will offer dried cannabis, pre-rolled and cannabis oil products across Canada at the advent of adult recreational use in 2018. Mined from a comprehensive research project that included the launch of ‘The Edison Project by OGI’ in November 2017, the Edison brand was founded on the ceaseless pursuit of improvement and innovation at Organigram.
The marquee sub-brand offered within the Edison family is Edison Reserve, a line of products that represents the best quality indoor grown product in the country. Edison Reserve product will only be available in larger pack sizes of dried flower, and will feature the Company’s top bud, hand manicured and craft cured for optimal consumer experience.
Organigram is Canada’s original organic cultivator; the subsequent progress and quality of product exists in the DNA of ANKR Organics. As a result of several years of research related to perfecting the art of organic cannabis cultivation and an ongoing partnership with a governing body, Organigram is poised to offer consumers the best quality organically-grown cannabis in the country. The Company continues to finalize plans for organic certification, which is planned for later in 2018.
Through an existing partnership with Trailer Park Productions, Organigram is proud to introduce Trailer Park Buds, a cannabis brand with a wink that speaks to consumers who appreciate a sense of humor and don’t take themselves too seriously. Focused on a value-conscious consumer who appreciates quality product, pre-rolled and blended products will be available at federally-licensed retail establishments across Canada in 2018.
Since 2014, Organigram has existed to help improve the lives of its patients through the federally-regulated medical cannabis system. Since that time, Organigram has grown to stand for a holistic approach to health focused on the pillars of quality, compassion, trust and consistency. Organigram will remain the Company’s primary medical brand.
Organigram Holdings Inc. is a company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
The company has a FYE of August 31st.
Q2 ending 2/28/2018
Total Revenue 3,688.773
Cost of Revenue -2,834.023
Gross Profit 6,522.796
Selling General and Administrative 3,148.703
Total Operating Expenses 1,468.305
Operating Income or Loss 2,220.468
Income from Continuing Operations
Total Other Income/Expenses Net -1,142.782
Earnings Before Interest and Taxes 2,220.468
Interest Expense -1,429.015
Income Before Tax 1,077.686
Net Income 1,077.686
Phase 3 expansion expected to be complete for the start of filling of rooms with first cannabis plants by June 1, 2018 bringing the Company’s pro-forma run-rate capacity to 36,000 kg/yr;
The Company intends to launch its adult-recreational brand strategy on or about May 15, 2018; and Organigram expects to announce one or more strategic or international investments in the upcoming quarter.
Stock influences and risk factors
The adult recreational use of cannabis in Canada, expected to be legalized in the summer of 2018, may act as a catalyst for company shares;
The most recent quarter was profitable, but the company has a history of losses;
The company may have to raise capital in the future for operations and/or acquisitions and such capital raises could be dilutive.
On Wednesday, May 30, 2018, OGRMF shares were at $3.90 on traded volume of 202K shares. The current RSI is 65.88
At $3.90 OGRMF shares are trading above their 50 DMA and 200 DMA of $3.59 and $2.93 respectively.